At present, GnRH-a down-regulation programs are commonly used in patients with endometriosis, adenomyosis, polycystic ovarian syndrome, patients with decreased ovarian reserve, and patients with repeated implantation failure. This evidence concerns the gene GNRH1 and polycystic ovary syndrome.